Immunotherapy is one of the greatest clinical care advancements of our time. We’ve known that ever since the pioneering work in bone marrow transplantation began more than 40 years ago.
Right now, Seattle Cancer Care Alliance (SCCA) is changing the way cancer is prevented, treated and cured. Our doctors and nurses are leaders in this revolutionary field. Here, we offer a broader range of immunotherapy options for cancer patients.
The promise of immunotherapy is boosting survival rates for patients with leukemia and other cancers. Our patients have access to a greater number of investigational immunotherapy treatments — using T cells, monoclonal antibodies and gene therapy—in clinical trials that are available at SCCA.
Center of Innovative Cancer Treatments
SCCA plays an important role in the development of these new immunotherapy drugs through its clinical trials program.
We’ve been on the forefront of medical advances for decades. Our legacy stems from the Nobel Prize-winning research of Fred Hutchinson Cancer Research Center (Fred Hutch), home to many of the leading authorities on the human immune system.
We developed this knowledge base both in our research labs and in our clinics, as we invented and refined the techniques that make bone marrow transplants possible—and increasingly effective.
Opened in December 2016, the Bezos Family Immunotherapy Clinic at SCCA doubles our capacity to conduct trials of promising new cellular immunotherapy. The clinic features:
- World-class oncology researchers and a support team of highly-trained nurses, technicians, clinicians and data experts: All working together to perfect a breakthrough cancer-fighting therapy that already has produced exceptional results.
- A unique facility that enables intensive monitoring of each patient to help doctors understand why some respond to experimental immune therapies and others do not, with the goal of developing curative approaches for every person with cancer.
- Doubling of our capacity for serving participants on our leading-edge immunotherapy clinical trials. Many of the patients seen at the new clinic, including the very first participant, went into complete remission on one of the clinical trials offered here.
- Hope to the many patients receiving care from the dedicated, expert staff, and it sets the bar for the entire field of clinical immunotherapy research.
Please keep in mind that immunotherapy therapies are not yet available for all types of cancer and, where available, they are effective only for a percentage of patients. If you are a patient or helping advise a cancer patient, we hope this information will enable you to ask good questions and have a more productive conversation with your providers.
Devoted care in expert hands
Our doctors not only know the latest clinical trials that may make a difference in treating your cancer. Many are lead investigators behind these studies:
- V.K. Gadi, MD, SCCA medical oncologist who specializes in breast cancer:“We can now go after cancer cells in a way that we never have before.”
- Shailender Bhatia, MD, SCCA medical oncologist who specializes in skin and kidney cancers:“Our immune system has the power to eradicate cancer cells completely. What we have seen over the last few years is that when stimulated the right way, the immune system can work really well.”
- Renato G. Martins, MD, MPH, SCCA medical director of thoracic/head and neck oncology as well as outpatient general oncology and hematology: “At SCCA, therapies that will become tomorrow’s standard of care are available today as clinical trials."
- Scott S. Tykodi, MD, SCCA medical oncologist who specializes in kidney cancer and melanoma: “Emerging favorable results with immunotherapies under development for lung, kidney, and other cancers and an ever-growing pipeline of novel immune-based agents tell us immunotherapies are certain to become increasingly prominent treatment options for our patients."
- Sylvia Lee, MD, SCCA medical oncologist who specializes in head and neck cancers, lung cancers, and melanoma:“Enhancing your own immune system’s natural ability to recognize and attack cancer cells is perhaps the most promising new form of treatment in a field long limited to surgery, chemotherapy, and radiation."
- Seth Pollack, MD, SCCA medical oncologist who specializes in sarcoma: “Survival rates are higher for patients who receive a sarcoma diagnosis and are treated early. More treatment options are still needed for patients living with a more advanced stage of the disease."